Dime Community Bancshares Q2 revenue hits record on loan growth
Reuters2026/07/23 11:13
Overview
US regional bank's Q2 revenue hit record on net interest margin expansion and loan growth
Adjusted diluted EPS for Q2 rose to $0.79 from $0.64 a year earlier
Company plans to resume share buybacks in Q3, citing strong capital position
Outlook
Dime expects to resume share buybacks in the third qtr
Company anticipates loan repricing opportunities to continue through 2027
Growth in core deposits and business loans expected to benefit results over time
Result Drivers
NET INTEREST MARGIN EXPANSION - Co said higher net interest margin was a key driver of record Q2 revenue
BUSINESS LOAN GROWTH - Co cited strong growth in business loans as a major contributor to Q2 results
CORE DEPOSIT GROWTH - Co reported substantial year-over-year growth in core deposits, supporting funding and margin
Company press release: ID:nGNX6Mb1c3
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q2 Net Income |
|
$34.81 mln |
|
Q2 Net Interest Income |
|
$115.19 mln |
|
Q2 Net Interest Margin (%) |
|
3.28% |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the banks peer group is "buy"
Wall Street's median 12-month price target for Dime Commercial Bancshares Inc is $46.00, about 16.6% above its July 22 closing price of $39.46
The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 9 three months ago
Reuters Recommended Reads
July 20 - ServisFirst Bancshares Q2 EPS rises 40% on loan growth, higher net interest margin
July 23 - Huntington Bancshares Q2 net income rises 39% sequentially on loan growth
July 21 - KeyCorp quarterly profit rises on interest income strength
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India
Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge
The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales
Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.
